Abstract | BACKGROUND: METHODS: RESULTS: At the end of follow-up, the sirolimus group showed a significant improvement in creatinine clearance (42.6 mL/min vs. 32.5 mL/min, P= 0.05), whereas the control group showed a significant reduction (32.3 mL/min vs. 40.3 mL/min, P= 0.02). The difference between the groups was statistically significant (P < 0.0001). Acute rejection episodes occurred in 2 patients in the sirolimus group and 1 patient in the control group (P= NS). Pneumonia developed in 6 study patients and 4 controls; all responded to antibiotics. CONCLUSION:
|
Authors | David Shitrit, Ruth Rahamimov, Sahar Gidon, Ilana Bakal, Ariella Bargil-Shitrit, Saute Milton, Mordechai R Kramer |
Journal | Kidney international
(Kidney Int)
Vol. 67
Issue 4
Pg. 1471-5
(Apr 2005)
ISSN: 0085-2538 [Print] United States |
PMID | 15780099
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Immunosuppressive Agents
- Creatinine
- Sirolimus
|
Topics |
- Aged
- Creatinine
(metabolism)
- Drug Therapy, Combination
- Emphysema
(surgery)
- Female
- Graft Survival
(drug effects)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Kidney Diseases
(immunology)
- Lung Transplantation
(adverse effects, immunology)
- Male
- Middle Aged
- Pilot Projects
- Postoperative Complications
(immunology)
- Sirolimus
(therapeutic use)
|